News

Astra Zeneca ends AZD2820 study
Enlarge image

BusinessSwedenUK

Astra Zeneca ends AZD2820 study

11.09.2012 - Swedish-British pharma Astra Zeneca has stopped the development of one obesity drug but promises to back partner Palatin with the other candidates.

US company Palatin Technologies, Inc. (Cranbury) experienced a setback for one of its developed drugs in June this year when its partner AstraZeneca PLC from Europe paused a Phase I clinical trial after a serious adverse event. Now, the Swedish-British pharma giant decided, after a thorough review, to end the development of this drug completely. However, Palatin also announced that AstraZeneca remains committed to the collaboration programme at large to discover, develop and commercialise compounds that target melanocortin-4 receptors for the treatment of obesity, diabetes and related metabolic syndrome.

The ditched clinical candidate called AZD2820 is a subcutaneously-administered peptide that partially agonises the melanocortin-4 receptor. Phase I clinical trials as a single-agent therapy for the treatment of obesity started in the first half of 2011 after AstraZeneca had selected the drug from the collaborative research programme with Palatin Technologies. The single centre study was expected to enrol 90 subjects with a body mass index between 30 and 35 in a randomised, single-blind, placebo-controlled, Phase I trial in healthy male volunteers. After 11 subjects had completed their dosing regimen, the trial was halted by the Safety Review Committee because it suspected that one subject may have had an allergic reaction following his first dose. The volunteer fully recovered but the review by AstraZeneca said that it cannot be excluded that the adverse reactiom was linked to AZD2820. The company however also stated, that it is unlikely that this event was related to melanocortin receptor activation as a mode of action.

BusinessSwitzerlandUK

23.04.2014 In an effort to focus on key businesses, pharma giant Novartis is joining forces with long-time rival GlaxoSmithKline in a multi-billion Euro asset exchange and an OTC joint venture.

FinanceSwedenFrance

18.04.2014 Oxthera AB, a Swedish biopharma company with a focus on rare diseases, has gained a SEK70m cash injection to continue its clinical programme for primary hyperoxaluria.

FundingEU

17.04.2014 The European Parliament has given green light to the second Innovative Medicines Initiative with the aim to advance pharmacological research and development, particularly in areas of unmet medical need.

BusinessGermanyFrance

15.04.2014 German flavour and scent specialist Symrise has announced its plans to acquire French pet-food ingredients maker Diana Group for €1.3bn.

BioeconomySpain

14.04.2014 Spanish Neol Biosolutions and the Center for Second Generation Biofuels are starting a partnership to scale-up Neol's waste-to-oil technology.

EvidenceUKSwitzerland

11.04.2014 There is no evidence that neuraminidase inhibitors Tamiflu and Relenza prevent complications of influenza or reduce hospital admissions. In addition, it is unclear whether they can stop the spread of influenza in case of outbreaks, says a report by the Cochrane Collaboration.

BusinessSwitzerlandSpain

09.04.2014 Roche is extending its involvement in the area of point-of-care diagnostics by taking over US company Iquum. In the field of epigenetics, the Swiss pharma company has started a cooperation with the Spanish company Oryzon.

Status ReportSwitzerland

08.04.2014 The Swiss Biotech Report 2014 presented in Zurich sees an encouraging upturn in the country's biotech scene. However, the acceptance of the mass immigration initiative poses a significant threat.

NanobiotechnologyItaly

07.04.2014 Scientists from the University of Udine have designed, produced and tested a prototype for a "DNA origami" nanorobot that can potentially deliver biological activators in-vivo.

EpidemicEUFranceGermanyItaly

02.04.2014 As the Ebola epidemic in Guinea worsens, Europe is deploying the specialists of EMLab to provide diagnostics at the focus of the outbreak.

Events

All Events

Partner-Events

München

BioVaria 2014

Frankfurt am Main

7th DVFA Life Science Conference

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • GW PHARMACEUTICALS (UK)305.50 GBP39.3%
  • NEWRON (CH)15.60 CHF20.0%
  • TOPOTARGET (DK)3.52 DKK16.9%

FLOP

  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.3%
  • WILEX (D)0.84 EUR-8.7%
  • GENFIT (F)22.42 EUR-8.1%

TOP

  • BIOTECH PHARMACON (N)18.80 NOK71.7%
  • WILEX (D)0.84 EUR47.4%
  • E-THERAPEUTICS (UK)27.75 GBP38.8%

FLOP

  • CYTOS (CH)0.17 CHF-93.8%
  • BIONOR PHARMA (N)2.11 NOK-47.3%
  • IMMUNICUM AB (S)16.60 SEK-36.2%

TOP

  • SILENCE THERAPEUTICS (UK)261.00 GBP6265.9%
  • IXICO (UK)68.00 GBP756.4%
  • PHARMING (NL)0.50 EUR733.3%

FLOP

  • CYTOS (CH)0.17 CHF-95.8%
  • EVOCUTIS (UK)0.22 GBP-91.8%
  • AGENNIX (D)0.04 EUR-77.8%

No liability assumed, Date: 23.04.2014